You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy

Article metrics

Article menu
Immune cell therapies and immune cell engineering
Original research
CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy

 

Online download statistics by month:

Online download statistics by month: March 2021 to August 2025

AbstractFullPdf
Mar 2021487487286
Apr 2021264264115
May 202117417461
Jun 202121521567
Jul 202116416447
Aug 202123923975
Sep 202116216287
Oct 202111311368
Nov 202112912979
Dec 202112512859
Jan 202215516355
Feb 202210510883
Mar 202210610759
Apr 202210211386
May 202217418270
Jun 202212112255
Jul 202211211593
Aug 2022808366
Sep 20229498126
Oct 2022869364
Nov 202212012349
Dec 202220720835
Jan 2023515230
Feb 202312612637
Mar 2023909154
Apr 202318118353
May 2023798045
Jun 2023575930
Jul 2023616747
Aug 2023494922
Sep 2023424225
Oct 2023677040
Nov 2023808022
Dec 2023959534
Jan 2024475145
Feb 2024535849
Mar 20248288126
Apr 2024747459
May 2024687456
Jun 2024777856
Jul 2024697130
Aug 20245452282
Sep 2024676846
Oct 2024767647
Nov 2024697045
Dec 2024858644
Jan 2025848460
Feb 2025717151
Mar 2025616148
Apr 2025838360
May 2025717148
Jun 2025303023
Jul 2025110
Aug 2025110
Total573558323399